ArticleFrontiers in oncology2026

Economic evaluation of newly approved cetuximab biosimilars for first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer in China.

Rui Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.